Kashiv BioSciences Private Limited, a leading biopharmaceutical company, has secured financing of Rs. 648 crore from the Union Bank of India to expand its state-of-the-art manufacturing facility in Pipan, near Ahmedabad. 

The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals. At full capacity, it is expected to manufacture up to 50,000 liters, marking a major step in Kashiv’s plan to strengthen its position as a global biopharma hub. 

“This funding marks a pivotal milestone in Kashiv’s journey to expand biomanufacturing capacity in India,” said Sandeep Athalye, Global CEO of Kashiv BioSciences. 

“The new facility in Pipan will not only accelerate innovation and access to high-quality biologics but also reinforce our commitment to building world-class infrastructure that supports global healthcare needs. This infrastructure is being financed with the support of the Union Bank of India and is in alignment with the Biotechnology Policy and schemes implemented by GSBTM (Gujarat State Biotechnology Mission), a body of the state government, which continues to catalyze investment in advanced biopharmaceutical manufacturing.” 

Serving markets across the US, Canada, Europe, and beyond, the facility aims to bolster India’s role as the “pharmacy of the world,” enhancing technical capabilities, improving global competitiveness, and creating high-value, long-term employment in scientific, technical, and operational fields. 

Digvijaysinh D Jadeja, Mission Director of GSBTM, added, “Kashiv’s expansion in Pipan exemplifies Gujarat’s commitment to fostering innovation-led growth in biotechnology. Through the Biotechnology Policy, we continue to support high-impact investments that elevate India’s scientific capabilities and create meaningful employment across the value chain.” 

A senior representative from the Union Bank of India said, “Union Bank is proud to have partnered with Kashiv as the lender on this initiative. This will advance India’s manufacturing capabilities and create sustainable economic value for the region, supporting the nation in achieving its goal of ‘Viksit and Atmanirbhar Bharat’. We wish the Company great success in this endeavour.”